Comparison of immunoassay- with mass spectrometry-derived p-tau quantification for the detection of Alzheimer's disease pathology.

ABSTRACT:

Background

Antibody-based immunoassays have enabled quantification of very low concentrations of phosphorylated tau (p-tau) protein forms in cerebrospinal fluid (CSF), aiding in the diagnosis of AD. Mass spectrometry enables absolute quantification of multiple p-tau variants within a single run. The goal of this study was to compare the performance of mass spectrometry assessments of p-tau₁₈₁, p-tau₂₁₇ and p-tau₂₃₁ with established immunoassay techniques.

Methods

We measured p-tau₁₈₁, p-tau₂₁₇ and p-tau₂₃₁ concentrations in CSF from 173 participants from the TRIAD cohort and 394 participants from the BioFINDER-2 cohort using both mass spectrometry and immunoassay methods. All subjects were clinically evaluated

SUBMITTER: Therriault J 

PROVIDER: S-EPMC10773025 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature